Clinical Impact of Secretion Management: Outcomes, Assessment, and Care

Counting airway-clearance treatments tells care teams how often support was provided, but not whether patients could clear secretions or how their respiratory care changed. The clinical impact of secretion management is best assessed through patient and care-process measures, interpreted in context. Secretion burden can affect respiratory care, but its effects and the measures that matter vary across patient populations.

For clinicians and care teams, the practical task is to connect assessment and treatment activity with meaningful outcomes. This article describes clinical consequences associated with ineffective secretion clearance and measures teams can consider, from patient-centred observations to care-process indicators. It also outlines a structured way to review those measures in local practice rather than relying on one measure for every population.

Secretion-management technology, including the EO-70 Secretion Management Device, can be considered within a clinically governed pathway. Align patient assessment, staff preparation, monitoring and outcome review so teams can evaluate care consistently and make informed decisions about airway-clearance support.

Why the Clinical Impact of Secretion Management Matters in Respiratory Care

Secretion management is the clinical assessment and support of a patient’s ability to handle or clear airway secretions. Its clinical impact is the observable effect secretion burden and clearance have on symptoms, respiratory events and care processes, interpreted in the context of the individual patient. This approach avoids assuming that the same secretion burden leads to the same outcome for everyone.

Assessment is more useful when teams distinguish three impact domains:

• Symptoms: Cough, breathlessness or difficulty clearing secretions may affect comfort and function. Record what the patient reports and when it occurs.
• Clinical events: Changes such as desaturation, suspected aspiration or respiratory complications may warrant assessment, but aren’t inevitable consequences of secretion burden.
• Care processes: Repeated assistance with clearance or interruptions to planned care can affect workload and workflow. Track these separately from patient outcomes.

Airway-clearance approaches differ according to patient need. The overview of Airway Clearance Therapy provides context on techniques and devices, while clinical decisions require individual assessment.

Which patients may experience secretion-clearance challenges?

Challenges can arise in pulmonary conditions where secretions are increased or difficult to move, and in neurological or neuromuscular contexts where cough strength, coordination or airway protection may be impaired. These involve different mechanisms: excess production increases the material to clear, while impaired cough or mucociliary clearance limits how effectively secretions move out of the airways. A patient may experience one issue or a combination. These examples are not an exhaustive diagnosis list.

What can ineffective clearance mean for patients?

When clearance is difficult, patients may experience persistent coughing, breathlessness, discomfort or difficulty managing oral and airway secretions. Presentation and severity vary. Aspiration and respiratory complications are risks to consider in relevant patients, not predictable outcomes for everyone with retained secretions. Clinicians can document symptoms, observed clearance ability and relevant events separately, then relate them to the patient’s condition and care goals. This keeps secretion burden clinically meaningful without treating one sign or intervention as proof of benefit.

How Secretion Management Can Influence Airway Clearance and Respiratory Care

Secretion characteristics, airway transport and cough effectiveness interact. The volume and consistency of secretions can affect how readily they move, while the patient’s ability to generate an effective cough influences whether material reaches the upper airway and can be expelled. Consider these factors together. Visible secretions alone do not provide a complete measure of clearance.

How do cough and mucociliary clearance affect secretion burden?

Microscopic cilia lining parts of the respiratory tract move mucus toward the throat, where it can be swallowed or cleared. Cough provides another means of moving secretions out. If ciliary transport or cough is impaired, clinicians may observe retained secretions, a weak or ineffective cough, or repeated need for assistance with clearance. These findings inform assessment. On their own, they don’t establish a diagnosis or determine the appropriate intervention.

Where can airway-clearance support fit into care?

Airway-clearance support can be considered as part of an individualized care plan, alongside assessment of respiratory status, patient tolerance, underlying condition and the intended clinical goal. The goal might be to support movement of retained secretions or assist a patient whose cough is ineffective. Defining that goal is separate from selecting a device or technique.

An airway-clearance intervention is selected to support a defined clinical goal through its intended mechanism; the intervention itself does not guarantee a particular outcome. The responsible clinical team determines whether support is appropriate, how it fits with other care and what findings should prompt reassessment, following applicable guidance and local processes. Document the intervention separately from the patient’s observed response and any change in care needs. Novus Medical offers the EO-70 Secretion Management Device as a respiratory-care technology option for clinical consideration. The clinical impact of secretion management should be interpreted through the patient’s response and care goal, not inferred from device use alone.

How Clinicians Can Assess the Impact of Secretion Management

A consistent evaluation sequence helps teams distinguish a treatment delivered from a meaningful change in patient status or care. To assess the clinical impact of secretion management, match each measure to the patient, setting, intervention and intended goal.

1. Define the baseline: Where feasible, record relevant symptoms, observed cough effectiveness, secretion burden and respiratory findings before the intervention.
2. Set a goal: Specify the intended change, such as supporting secretion clearance or improving comfort. Keep the goal relevant to the individual patient.
3. Choose measures: Select patient-reported, observed or service indicators that directly relate to the goal.
4. Reassess: Repeat observations at intervals set by the care team and local protocol. Use consistent documentation.
5. Interpret: Review findings in context, including concurrent care and changes in the patient’s condition.

Which patient-centred outcomes can teams consider?

Patient-centred measures may include reported discomfort or breathlessness, perceived difficulty clearing secretions and tolerance of support. Clinical observations can include secretion burden, cough effectiveness and relevant respiratory findings. To make comparisons useful, document the measure, the observation period and the context in which it was recorded. Established assessment tools may support consistency when appropriate to the patient and care context. Avoid applying a tool outside the population or purpose for which it is suitable.

How can teams track care processes responsibly?

Local protocols can specify what to document, who records it and when reassessment occurs. Service indicators, such as the frequency of assistance or interruptions to planned care, should be recorded separately from patient outcomes. Use shared definitions across the team. When reviewing trends, consider the patient’s clinical context and concurrent care rather than attributing a change to one intervention alone.

An observed change after an intervention does not, by itself, establish that the intervention caused the change. Consider timing, other care and the overall clinical picture before drawing conclusions. For a secretion-management technology option within a defined pathway, review the EO-70 Secretion Management Device.

Integrating Secretion-Management Technology Into a Clinical Pathway

Technology is most useful when its role is defined within a care pathway, rather than treated as a stand-alone intervention. Before implementation, align patient selection and use with the device’s intended use, approved product information and local protocols. Governance should also specify who oversees the pathway, how staff competency is supported, and how patient response and workflow concerns are reviewed.

What should a facility define before implementation?

Set out the clinical goals, responsible roles and documentation expectations before introducing a device. Identify which staff need education and how competency will be supported. Define how the team will record relevant observations, review patient response and report device or workflow concerns. A practical pathway states what information to capture, who is responsible for recording it and how findings will be reviewed. This supports consistent practice while allowing the clinical team to adapt decisions to individual patients and their care context.

• Clinical governance: Assign oversight and define how the pathway aligns with facility protocols.
• Patient selection: Base decisions on clinical assessment and the device’s approved information.
• Staff preparation: Identify training needs and clarify responsibilities for use and documentation.
• Outcome review: Set a process for reviewing patient response and operational concerns.

Review should distinguish whether the device was used as planned from what was observed afterward. A change in symptoms, clinical findings or workflow can inform pathway evaluation, but interpretation belongs within the broader clinical context. Consistent documentation supports that review and can identify where staff education or local processes may need attention. This is how teams can assess the clinical impact of secretion management without assuming a device alone determines an outcome.

How can Novus Medical support Canadian care teams?

The EO-70 Secretion Management Device is part of Novus Medical’s respiratory-care portfolio in Canada. Novus Medical provides Canadian-based technical support and warranty services for healthcare providers. These supports can form part of implementation planning alongside staff education, monitoring and the facility’s established processes.

Make the Next Step a Measurable One

Turn local evaluation into a practical next step: choose one patient group or care setting, identify a clear clinical question, and agree in advance how the team will document and review findings. For example, a review can focus on whether the selected measures capture the intended goal and whether staff can apply them consistently. Keep decisions grounded in individual assessment and your facility’s established protocols.

The clinical impact of secretion management is not a result to assume in advance. It is a question care teams can examine through thoughtful measurement, shared interpretation and ongoing pathway review. When considering technology options, connect the intended clinical role with the support needed for implementation.

Explore Novus Medical’s respiratory-care solutions and discuss how the EO-70 Secretion Management Device can fit within your facility’s approach. Define the clinical goal, measures and review process before implementation.

Frequently Asked Questions

What is secretion management?

Secretion management is an umbrella term, not the name of one procedure. In clinical records and handoffs, specifying the particular concern makes the plan clearer for the next team member. For example, note whether the patient needs assistance with airway secretions or whether the concern involves managing oral secretions. Use terminology that reflects the patient’s situation and the care being provided.

How can secretion management affect respiratory care?

Secretion-related needs can affect how teams coordinate care during a shift change or transfer between settings. A concise handoff can state what assistance the patient has needed, what the patient has tolerated and whether the observed situation has changed. This supports continuity without assuming that a symptom or event has the same meaning for every patient.

Can secretion-management devices improve patient outcomes?

A device may form part of care intended to support a patient-specific goal, but its presence or use shouldn’t be treated as an outcome in itself. During local review, teams can also consider whether the device fits established workflows and whether patients tolerate its use. These implementation observations provide context for clinical review, but they don’t establish that the device caused a change in health status.

How do clinicians measure the impact of secretion management?

For patients who can’t reliably describe their experience, teams can select observable measures suited to the patient’s communication and developmental abilities. In paediatric care, for example, an observation-based approach may be more appropriate than relying only on verbal symptom reports. Choose measures staff can apply consistently and interpret them according to the patient’s context, rather than treating one observation as a complete account.

Who may need secretion-management support?

The need for support can be temporary or change as a patient’s condition and care setting change. A person may require a different level of assistance during an acute episode than during a later phase of care. Reconsidering the plan after a meaningful change in clinical status or during a transition between care settings can help the team keep support aligned with current needs.